Search

JP-7856645-B2 - Ciliary groove implants and methods for using ciliary groove implants

JP7856645B2JP 7856645 B2JP7856645 B2JP 7856645B2JP-7856645-B2

Inventors

  • ケーブル ザ セカンド、クレイグ アラン
  • カフーク、マリック ワイ．
  • サスマン、グレン アール．
  • デネウィル、ジェームズ アール．

Assignees

  • スパイグラス ファーマ インコーポレイテッド
  • ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト

Dates

Publication Date
20260511
Application Date
20211028
Priority Date
20201028

Claims (14)

  1. An ophthalmic implant configured to be implanted in the target eye, The aforementioned ophthalmic implant is A ring (15) configured to be embedded in the eye of the subject, comprising an outer surface, an inner wall, and a central opening (17) without a lens , It comprises a haptic (16, 16L, 43, 46) connected to the ring at a first haptic end (16d, 41, 45) and a second haptic end (16d, 42, 44), The ring is provided with holes (18, 49, 50) that extend from the openings (19, 51) on the outer surface toward the inner wall, An ophthalmic implant in which the second haptic ends (16d, 42, 44) are positioned within and slidably within the holes (18, 48, 50, 52), thereby allowing the haptic to be deformed by a force applied by the tissue in which the ophthalmic implant is embedded, which can push the second haptic ends into the holes (18, 48, 50, 52).
  2. The ophthalmic implant according to claim 1, wherein the second haptic end (16d, 42, 44) comprises a haptic distal tip (16T) having a larger cross-section than the remainder of the second haptic end (16d, 42, 44).
  3. The ophthalmic implant according to claim 1 or 2, wherein the second haptic end (16d, 42, 44) comprises a haptic distal tip (16T) having a larger cross-section than the remainder of the second haptic end (16d, 42, 44), and the hole (18, 36, 48, 50) has a lumen having a smaller cross-section than the haptic distal tip (16T), thereby preventing or stopping the second haptic end from dislodging from the hole.
  4. The ophthalmic implant according to any one of claims 1 to 3, further comprising a gripping feature (21) positioned on the second haptic end (16d, 42 , 44), wherein the gripping feature is configured for engaging a gripping device.
  5. The ophthalmic implant according to any one of claims 1 to 4, wherein the holes (18, 50) extending from the openings (19, 51) on the outer circumferential surface toward the inner wall are through holes communicating with the openings (20, 56) in the inner wall of the ring, the second haptic end (16d, 42, 44) comprises a haptic distal tip (16T) having a larger cross-section than the remainder of the second haptic end (16d, 42, 44 ), and the haptic distal tip (16T) is positioned in the central opening (17).
  6. The ophthalmic implant according to any one of claims 1 to 5, wherein the first haptic end (16d, 41, 45) comprises a haptic distal end (16T) having a larger cross-section than the remainder of the first haptic end (16d, 41, 45 ).
  7. The ophthalmic implant according to any one of claims 1 to 6, wherein the first haptic end (16d, 41, 45) comprises a haptic distal tip (16T) having a larger cross-section than the remainder of the first haptic end, and the hole (18, 47, 49 ) has a lumen having a smaller cross-section than the haptic distal tip (16T), thereby preventing or stopping the first haptic end from dislodging from the hole.
  8. The ophthalmic implant according to any one of claims 1 to 7, wherein the holes (18, 50) are first holes, the ring (15) further comprises a second hole extending from a second opening on the outer circumferential surface toward the inner wall, and the first haptic end (16d, 41, 45) is positioned within the second hole and slidably positioned within the hole, so that the haptic is deformable by a force applied by the tissue in which the ophthalmic implant is embedded, which pushes the first haptic end (16d, 41 , 45) into the second hole.
  9. The ophthalmic implant according to any one of claims 1 to 8 , wherein the haptic (16, 16L, 43, 46) forms a closed loop between the first haptic end (16d, 41, 45) and the second haptic end (16d, 42, 44).
  10. The ophthalmic implant according to any one of claims 1 to 9 , further comprising drug delivery structures (27, 81, 82) configured to be coupled to the ring (15).
  11. The ophthalmic implant according to claim 10 , wherein the drug delivery structure (27, 81, 82) contains a therapeutic agent.
  12. The ophthalmic implant according to claim 11 , wherein the therapeutic agent is arranged in a polymer matrix.
  13. The aforementioned therapeutic agent includes one or more of the following: prostaglandin analogs, alpha agonists, Rho-kinase (ROCK) inhibitors, adenosine receptor agonists, carbonic anhydrase inhibitors, adrenergic and/or cholinergic receptor activators, steroids, aptamers, complement factors, antioxidants, anti-inflammatory drugs, antibodies, antiproliferative agents, antimitotic agents, or anti-inflammatory drugs. The ophthalmic implant according to claim 11 or 12 , wherein the therapeutic agent comprises bimatoprost.
  14. The ophthalmic implant according to any one of claims 10 to 13, wherein the drug delivery structure (27, 81, 82) is coupled to the rear surface of the ring (15), or the drug delivery structure (27, 81, 82) comprises a pair of arc-shaped structures coupled to the ring ( 15 ) .

Description

This invention relates to a ciliary groove implant and a method for using a ciliary groove implant. Conventional intraocular implants sometimes have limitations in terms of their manufacturability and their ability to provide therapeutic effects without damaging ocular tissue upon implantation. Therefore, there are unmet requirements for intraocular implants that will improve safety during use, reduce tissue damage, and improve manufacturability. A diagram illustrating the operating environment of an intraocular drug delivery system.A diagram illustrating the operating environment of an intraocular drug delivery system.Figure 2 shows a drug delivery platform configured for use in the ciliary sulcus of the eye.Side view of Figure 3.Figures 2 and 3 show front perspective views of the drug delivery platform.This shows a drug delivery system configured to allow posterior access to the haptic tip.This shows a drug delivery system configured to allow posterior access to the haptic tip.A diagram showing the ciliary groove (sulcus) IOL, which is constructed with the characteristics of the captured haptic tip.Side views showing the front opening of the through-hole of the device in Figures 6 to 8.Figures 2 to 7 show modified examples that can be applied to the devices.A diagram showing a drug delivery platform combined with an implant configured for use in the ciliary sulcus of the eye, which has one or more aqueous humor flow holes.Figure 11 shows a forward perspective view of the drug delivery platform.Figure 11 shows a forward perspective view of the drug delivery platform.A diagram showing the ciliary sulcus lens modified by the aqueous humor opening.A figure showing a drug delivery ciliary sulcus implant configured for use in the ciliary sulcus of the eye, according to an embodiment of the present disclosure.Figure 15 shows a drug delivery ciliary groove implant in a compressed form according to an embodiment of the present disclosure.A diagram showing a drug delivery platform in which a biasing member is integrally formed with a drug delivery structure according to an embodiment of the present disclosure.Figure 17 shows a compressed form of a drug delivery platform in which a biasing member is integrally formed with a drug delivery structure, according to an embodiment of the present disclosure.A diagram showing a drug delivery platform having a single arc-shaped drug delivery structure according to an embodiment of the present disclosure.A diagram illustrating a drug delivery platform comprising a drug delivery device having an elastically expandable and compressible wireframe according to an embodiment of the present disclosure.A diagram illustrating a drug delivery platform comprising a drug delivery device having an elastically expandable and compressible ring according to an embodiment of the present disclosure.This figure shows a drug delivery platform comprising a drug delivery device having an elastically expandable and compressible ring according to an embodiment of the present disclosure, with the device shown in Figure 21 in a compressed state.A diagram illustrating a drug delivery platform comprising closed-loop haptics and A-shaped haptics according to an embodiment of the present disclosure.A diagram illustrating a drug delivery platform comprising closed-loop haptics and retention features according to an embodiment of the present disclosure.A diagram illustrating a drug delivery platform comprising closed-loop haptics and A-shaped haptics according to an embodiment of the present disclosure.A diagram illustrating a drug delivery platform comprising multiple closed-loop haptics attached to a compressible partial ring according to an embodiment of the present disclosure.A diagram showing a drug delivery platform in which a biasing member is integrally formed with a drug delivery structure according to an embodiment of the present disclosure. This disclosure provides an intraocular device for implantation in the target eye. The device provided herein can be implanted in various regions of the target eye. In various embodiments, this specification provides an intraocular device for implantation in the ciliary sulcus of the target eye, as described herein. As used herein, unless otherwise defined, terms such as “ophthalmic device,” “ophthalmic implant,” and “intraocular device” may be used interchangeably and generally refer to a device that can be implanted in one or more specific locations within the eye of a subject (e.g., a human eye). Figures 1 and 2 show the arrangement and use of an intraocular drug delivery system or other ocular implant in the eye of the subject. The eye 1 comprises a lens 2 and lens capsule 3, an anterior chamber 4 containing the cornea 5 and iris 6, and aqueous humor filling the space between the cornea and the iris, and a posterior chamber 7 between the iris and the lens capsule. The posterior space/vitreous humor 8 is the large space between the lens and the retina 9. T